Synopsis: Rossari Biotech’s subsidiary, Unitop Chemicals, has fully commissioned a 30,000 MTPA ethoxylation expansion in Gujarat, doubling its total capacity to 66,000 MTPA to meet surging FMCG and industrial demand.
Rossari Biotech Limited (ROSSARI) has successfully commissioned the final 15,000 MTPA tranche of its ethoxylation capacity expansion at its Dahej facility in Gujarat. This milestone, effective March 31, 2026, completes a total planned expansion of 30,000 MTPA first announced in October 2023. With this addition, the total installed capacity for its material subsidiary, Unitop Chemicals, now stands at 66,000 MTPA.
The project was executed in two stages and finished on schedule, significantly boosting Rossari’s production of ethoxylated surfactants for the FMCG, agrochemical, and industrial sectors. This domestic scaling follows a recent Board approval for a $10 million investment into a new Singapore-owned subsidiary, signaling an aggressive push to expand the company’s international footprint.
Rossari Biotech Limited’s stock, with a market capitalisation of Rs. 2,243 crores, rose to Rs. 406.05 hitting a high of up to 7.2 percent from its previous closing price of Rs. 378.60. Furthermore, the stock over the past year has given a negative return of 34 percent.
The stock’s performance reflects a period of significant correction, declining by 18.53% over the last month and 31.51%over a three-month period. On a year-on-year basis, the shares have fallen 32.55%, currently trading well below the 52-week high of ₹766. This downward trend persists despite the company’s recent 30,000 MTPA capacity expansion at its Dahej facility.
Company Overview
Established in 2003, Rossari Biotech is a leading specialty chemicals manufacturer serving over 25 countries across home care, textile, and animal nutrition sectors. Operating from Dahej and Silvassa, the firm recently doubled its subsidiary Unitop’s ethoxylation capacity to 66,000 MTPA to meet surging global FMCG and industrial demand.
In Q3 FY26, the company reported a 13.45% revenue increase to ₹581.68 crore, yielding a net profit of ₹32.77 crore. With its expanded 66,000 MTPA capacity now operational, Rossari Biotech is primed to leverage its manufacturing scale to drive international growth and market dominance.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Rossari Biotech stock jumps 7.2% after its Subsidiary Completes Massive 30,000 MTPA Capacity Expansion at Dahej appeared first on Trade Brains.